Lv1
20 积分 2022-09-02 加入
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
13小时前
待确认
Tumour burden and efficacy of immune-checkpoint inhibitors
1个月前
已完结
MicroRNA-21 (miR-21) in Breast Cancer: From Apoptosis Dysregulation to Therapeutic Opportunities
1个月前
已完结
MicroRNAs won the Nobel — will they ever be useful as medicines?
1个月前
已完结
Abstract 2125: Roles of KAT6A and KAT6B in the biology of estrogen positive breast cancer
3个月前
已关闭
The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer
3个月前
已完结
Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician's perspective
3个月前
已关闭
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer
5个月前
已完结
Blinded sample size reestimation in event‐driven clinical trials: Methods and an application in multiple sclerosis
6个月前
已完结
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study
6个月前
已完结
皖公网安备34019202002308
